Testing a new drug combination before prostate cancer surgery

This trial is testing whether a new medication called relacorilant, when combined with enzalutamide (a standard hormone-blocking drug), can improve outcomes before prostate cancer surgery. Researchers want to see if this combination is safe and whether it helps shrink tumors and delay the spread of cancer to other parts of the body in men with high-risk prostate cancer.

Prostate cancer cells need hormones to grow, so doctors use hormone-blocking medications to slow them down. This trial is testing whether adding a second medication to the standard approach might work even better, especially for men with more advanced cases.